

Companion Diagnostics: Technologies and Markets

<https://marketpublishers.com/r/C2893219268EN.html>

Date: May 2023

Pages: 286

Price: US\$ 5,500.00 (Single User License)

ID: C2893219268EN

Abstracts

Report Scope:

The current report provides detailed coverage of the companion diagnostics market. This report highlights the current and future market potential of companion diagnostics, and it includes a detailed analysis of the drivers, opportunities, restraints and challenges in the market. The report also features market projections to 2027 and market ranking for key market players. It also covers the competitive environment and regulatory scenario. The report details the companion diagnostics market share based on product and Service, type of test, technology and application. The market is segmented based on product and Service into instruments, consumables and services. It is categorized based on the type of test into commercial CDx and lab-developed tests (LDT)-CDx. Based on technology, the market is segmented into polymerase chain reaction, immunohistochemistry, next-generation sequencing, in situ hybridization, genotyping, others, and services. Based on the application, the companion diagnostics market is segmented into cancer, neurologic disorders, cardiovascular disease, infectious disease and others. The report includes company profiles of the key players in the companion diagnostics market with detailed information about each company's business segments, financials, product portfolios and recent developments. The report also covers the impact of the COVID-19 pandemic on this market.

By geography, the market has been segregated into North America, Europe, Asia-Pacific and the Rest of the world. The North American region includes countries such as the U.S. and Canada; Europe includes Germany, U.K., Italy, France, and the Rest of Europe; Asia-Pacific includes China, India, Japan, and the Rest of Asia-Pacific. For market estimates, data has been provided for 2019 as the historic year, 2021 as the base year and 2027 as the forecast year.

Report Includes:

43 data tables and 60 additional tables

Detailed overview and an up-to-date analysis of the global market for companion diagnostics (CDx)

Analyses of the global market trends, with historic market revenue data for 2019-2021, estimates for 2022, and projections of compound annual growth rates (CAGRs) through 2027

Estimation of the actual market size and revenue forecast for the global CDx market in USD million values, and corresponding market share analysis by product and service, technology, application, type of test, and region

Identification of the viable technology drivers and barriers through a holistic review of various platform technologies and their potential applications in the development of new CDx products

Discussion of feasible market opportunities for companion diagnostics products via identification of high-growth applications in different therapeutic areas, with a focus on the biggest and fastest-expanding markets for diseases

Updated information on recent market developments and clinical trials, as well as the leading companies engaged in research and development (R&D) and products in the companion diagnostics reagent pipeline with SWOT analyses

Review of the patents and patent applications on companion diagnostics and deep dive of recent patent publications related to CDx products and technologies

Insight into the recent industry structure of companion diagnostics, competitive aspects of each product segments, increasing investment on R&D activities, market growth strategies, and company revenue share analysis

Descriptive company profiles of the leading global players, including Abbott Laboratories, Bio-Rad Laboratories Inc., Illumina Inc., Foundation Medicine Inc., Myriad Genetics Inc., F. Hoffmann-La Roche Ltd., Qiagen N.V., and Thermo Fisher Scientific Inc.

Contents

CHAPTER 1 INTRODUCTION

- 1.1 Overview
- 1.2 Study Goals and Objectives
- 1.3 Reasons for Doing This Study
- 1.4 What's New in This Update?
- 1.5 Scope of Report
- 1.6 Information Sources
- 1.7 Research Methodology
- 1.8 Geographic Breakdown
- 1.9 Analyst's Credentials
- 1.10 BCC Custom Research
- 1.11 Related BCC Research Reports

CHAPTER 2 SUMMARY AND HIGHLIGHTS

- 2.1 Highlights of the Market for Companion Diagnostics (CDx)

CHAPTER 3 MARKET AND TECHNOLOGY BACKGROUND

- 3.1 Introduction
- 3.2 Personalized Medicine and Biomarkers
 - 3.2.1 Predictive Biomarkers
- 3.3 Companion Diagnostics and Complementary Diagnostics
 - 3.3.1 Companion Diagnostics Development
 - 3.3.2 CDx Stakeholders
 - 3.3.3 Technologies Used in CDx
 - 3.3.4 Applications of CDx
 - 3.3.5 Regulatory Aspects of CDx

CHAPTER 4 GLOBAL MARKET FOR COMPANION DIAGNOSTICS BY PRODUCT AND SERVICE

- 4.1 Market Overview
- 4.2 Market Share and Forecast
 - 4.2.1 Instruments
 - 4.2.2 Consumables

4.2.3 Services

CHAPTER 5 GLOBAL MARKET FOR COMPANION DIAGNOSTICS BY TYPE OF TEST

5.1 Market Overview

5.2 Market Share and Forecast

5.2.1 LDT-CDx

5.2.2 Commercial CDx

CHAPTER 6 GLOBAL MARKET FOR COMPANION DIAGNOSTICS BY TECHNOLOGY

6.1 Market Overview

6.2 Market Share and Forecast

6.2.1 Immunohistochemistry

6.2.2 In Situ Hybridization

6.2.3 Polymerase Chain Reaction

6.2.4 Next-Generation Sequencing

6.2.5 Genotyping

6.2.6 Others

6.2.7 Services

CHAPTER 7 GLOBAL MARKET FOR COMPANION DIAGNOSTICS BY APPLICATION

7.1 Market Overview

7.2 Market Share and Forecast

7.2.1 Cancer

7.2.2 Market for the Application of CDx in Cancer by Type

7.2.3 Neurologic Disorders

7.2.4 Cardiovascular Disease

7.2.5 Infectious Disease

7.2.6 Other Diseases

CHAPTER 8 GLOBAL MARKET FOR COMPANION DIAGNOSTICS BY REGION

8.1 North America

8.1.1 U.S.

- 8.1.2 Canada
- 8.2 Europe
 - 8.2.1 Germany
 - 8.2.2 U.K.
 - 8.2.3 France
 - 8.2.4 Italy
 - 8.2.5 Rest of Europe
- 8.3 Asia-Pacific
 - 8.3.1 China
 - 8.3.2 Japan
 - 8.3.3 India
 - 8.3.4 Rest of Asia-Pacific
- 8.4 Rest of the World

CHAPTER 9 INDUSTRY STRUCTURE

- 9.1 Overview
- 9.2 Stakeholders in Companion Diagnostics
- 9.3 Driving Trends in Companion Diagnostics
- 9.4 Business Models of Companion Diagnostics
- 9.5 Grants and Funding in Companion Diagnostics
- 9.6 Collaborations and Partnerships
- 9.7 Mergers and Acquisitions
 - 9.7.1 Market Share Analysis
- 9.8 Leading Market Players in Companion Diagnostics Market, by Technology
 - 9.8.1 Leading Market Players in IHC Market
 - 9.8.2 Leading Market Players in ISH Market
 - 9.8.3 Leading Market Players in PCR Market
 - 9.8.4 Leading Market Players in NGS Market
 - 9.8.5 Leading Market Players in Genotyping Market
 - 9.8.6 Leading Market Players in Others (Tropism, MRI) CDx Market

CHAPTER 10 PATENT REVIEW

- 10.1 Introduction
- 10.2 Patents on Companion Diagnostics Market
- 10.3 Patent Analysis
 - 10.3.1 Patents by Year
 - 10.3.2 Patents by Top Applicant

- 10.3.3 Patents by Top Owner
- 10.3.4 Patents by Jurisdiction

CHAPTER 11 CLINICAL TRIALS ANALYSIS

- 11.1 Introduction
- 11.2 Clinical Trials and CDx
- 11.3 Clinical Trials Analysis
 - 11.3.1 Clinical Trials Analysis, by Type of Study
 - 11.3.2 Clinical Trials Analysis, by Status
 - 11.3.3 Clinical Trials Analysis, by Phase
 - 11.3.4 Clinical Trials Analysis, by Region
 - 11.3.5 Clinical Trials Analysis, by Application
 - 11.3.6 Companies with Companion Diagnostics in Clinical Trials

CHAPTER 12 ANALYSIS OF MARKET OPPORTUNITIES

- 12.1 Introduction
- 12.2 Market Dynamics
 - 12.2.1 Strengths
 - 12.2.2 Challenges
 - 12.2.3 Opportunities
 - 12.2.4 Threats
- 12.3 Impact of the COVID-19 Pandemic

CHAPTER 13 COMPANY PROFILES

ABBOTT
ADAPTIVE BIOTECHNOLOGIES CORP.
AGILENT TECHNOLOGIES INC.
AMOY DIAGNOSTICS CO., LTD.
ALMAC GROUP LTD.
ARUP LABORATORIES
AUTOGENOMICS INC. (ACQUIRED BY PRESCIENT MEDICINE)
BIOCARTIS
BIODESIX INC.
BIOFLUIDICA
BIOMERIEUX SA
BIO-TECHNE

CERBA RESEARCH
CIRCULOGENE
DANAHER
DIASORIN S.P.A.
EXACT SCIENCES CORP.
F. HOFFMANN-LA ROCHE LTD.
GUARDANT HEALTH INC.
HOLOGIC INC.
ICON PLC
ILLUMINA INC.
INVIVOSCRIBE INC.
MAZE THERAPEUTICS
MYRIAD GENETICS INC.
NEOGENOMICS LABORATORIES
QIAGEN
QUEST DIAGNOSTICS INC.
RESONANCE HEALTH LTD.
SIEMENS HEALTHINEERS AG
SPARTAN BIOSCIENCE INC.
SYSMEX CORP.
THERMO FISHER SCIENTIFIC INC.
TRIMGEN CORP.
VELA DIAGNOSTICS INC.

CHAPTER 14 APPENDIX: ACRONYMS

List Of Tables

LIST OF TABLES

- Summary Table A: Global Market for Companion Diagnostics, by Product and Service, Through 2027
- Summary Table B: Global Market for Companion Diagnostics, by Region, Through 2027
- Table 1: Examples of Predictive Biomarkers
- Table 2: Biomarkers Used in Companion Diagnostics
- Table 3: Commercial CDx vs. LDT-CDx
- Table 4: Examples of Technologies Used in Different CDx
- Table 5: FDA List of Pharmacogenetic Associations for which the Data Support Therapeutic Management Recommendations
- Table 6: Different Agents Used for Chemotherapy and Targeted Therapy
- Table 7: Comparison Between Chemotherapy and Targeted Therapy
- Table 8: Differences Among PMA, HDE and 510(k) Applications for CDx
- Table 9: CLIA Categorization Criteria
- Table 10: Regulatory Approvals Granted for CDx
- Table 11: Global Market for Companion Diagnostics, by Product and Service, Through 2027
- Table 12: Companion Diagnostics Instruments
- Table 13: Global Market for Companion Diagnostics Instruments, by Region, Through 2027
- Table 14: Global Market for Companion Diagnostics Consumables, by Region, Through 2027
- Table 15: Global Market for Companion Diagnostics Services, by Region, Through 2027
- Table 16: Global Market for Companion Diagnostics, by Type of Test, Through 2027
- Table 17: Laboratory Developed Test (LDT) Assays Approved by the FDA as a Companion Diagnostics (CDx)
- Table 18: Global Market for Laboratory Developed Test (LDT)-CDx, by Region, Through 2027
- Table 19: FDA Approved Companion Diagnostics, March 2023
- Table 20: Global Market for Commercial-CDx, by Region, Through 2027
- Table 21: FDA-Approved CDx Technologies, by Year, 2000–June 2021
- Table 22: Number and Percentage of FDA-Approved CDx Tests, by Technology, 2000–June 2021
- Table 23: Global Market for Companion Diagnostics, by Technology, Through 2027
- Table 24: FDA-Approved IHC-CDx
- Table 25: Global Market for Immunohistochemistry CDx, by Region, Through 2027

- Table 26: FDA-Approved ISH-CDx
- Table 27: Global Market for In Situ Hybridization CDx, by Region, Through 2027
- Table 28: FDA-Approved PCR-CDx
- Table 29: Global Market for Polymerase Chain Reaction CDx, by Region, Through 2027
- Table 30: FDA-Approved NGS-CDx
- Table 31: Foundation Medicine CDx: Indications and Biomarkers
- Table 32: Global Market for Next-Generation Sequencing CDx, by Region, Through 2027
- Table 33: FDA-Cleared Pharmacogenetic Tests
- Table 34: Global Market for Genotyping CDx, by Region, Through 2027
- Table 35: Global Market for Other CDx Technologies, by Region, Through 2026
- Table 36: Technological Expertise in CDx Services Sector
- Table 37: Global Market for CDx Services, by Region, Through 2027
- Table 38: Global Market for Companion Diagnostics, by Application, Through 2027
- Table 39: Drugs with Approved Companion Diagnostics
- Table 40: Global Market for Companion Diagnostics in Cancer Applications, by Region, Through 2027
- Table 41: Cancer Incidence, Global, by Cancer Type, 2020
- Table 42: Total Number of Drugs with Approved CDx, by Cancer Type, 2021
- Table 43: Global Market for Companion Diagnostics in Cancer Applications, by Cancer Type, Through 2027
- Table 44: Global Market for Companion Diagnostics in Neurologic Disorders Applications, by Region, Through 2027
- Table 45: Estimated Deaths Due to Cardiovascular Disease, by Gender and Disease, 2019
- Table 46: Global Market for Companion Diagnostics in Cardiovascular Disease Application, by Region, Through 2027
- Table 47: Classes of ART
- Table 48: Global Market for Companion Diagnostics in Infectious Disease Application, by Region, Through 2027
- Table 49: Global Market for Companion Diagnostics in Other Disease Applications, by Region, Through 2027
- Table 50: Global Market for Companion Diagnostics, by Region, Through 2027
- Table 51: North American Market for Companion Diagnostics, by Country, Through 2027
- Table 52: U.S. Estimated Number of New Cancer Cases, by Cancer Site, 2021
- Table 53: European Market for Companion Diagnostics, by Country, Through 2027
- Table 54: Asia-Pacific Market for Companion Diagnostics, by Country, Through 2027
- Table 55: Grants and Funding in Companion Diagnostics, 2019–July 15, 2020

Table 56: Collaborations and Partnerships in the Global Companion Diagnostics Market, 2019–February 2023

Table 57: Mergers and Acquisitions in the Global Companion Diagnostics Market, 2019-2020

Table 58: Companion Diagnostics: Market Share Analysis

Table 59: IHC Companion Diagnostics, Product

Table 60: Leading Market Players of IHC Companion Diagnostics, 2021

Table 61: ISH Companion Diagnostics, Product

Table 62: Leading Market Players of ISH Companion Diagnostics, 2021

Table 63: PCR Companion Diagnostics, Product

Table 64: Leading Market Players of PCR Companion Diagnostics, 2021

Table 65: NGS Companion Diagnostics, Products

Table 66: Leading Market Players of NGS Companion Diagnostics, 2021

Table 67: Genotyping Companion Diagnostics, Products

Table 68: Leading Market Players of Genotyping Companion Diagnostics, 2021

Table 69: Other Companion Diagnostics, Products

Table 70: Leading Market Players of Other Companion Diagnostics, 2021

Table 71: Basic Aspects of Patents

Table 72: Representative Patents on Companion Diagnostics, 2018–June 2021

Table 73: Number of Patents Issued on Companion Diagnostics, by Top Applicant, 2018-2022

Table 74: Number of Patents Issued on Companion Diagnostics, by Top Owner, 2018-2022

Table 75: Number of Patents Issued on Companion Diagnostics, by Jurisdiction, 2017-2022

Table 76: Clinical Trials on Companion Diagnostics, by Type of Study, March 2023

Table 77: Clinical Trials on Companion Diagnostics, by Status, March 2023

Table 78: Clinical Trials on Companion Diagnostics, by Phase, March 2023

Table 79: Clinical Trials on Companion Diagnostics, by Region, March 2023

Table 80: Clinical Trials on Companion Diagnostics, by Application, March 2023

Table 81: Companies with CDx in Clinical Trials, March 2023

Table 82: Companion Diagnostics and Approved Drugs, 2020-2022

Table 83: FoundationOne CDx Approved Indications

Table 84: Common Inefficiencies in Clinical Testing Landscape

Table 85: Initiatives Towards Harmonization of Commercial and LDT-CDx

Table 86: All of Us Research Program Highlights

Table 87: Abbott: Product Portfolio

Table 88: Agilent Technologies Inc.: Product Portfolio

Table 89: Agilent Technologies Inc: Key Developments, 2021-2023

Table 90: Amoy Diagnostics: Key Developments, 2020-2022

Table 91: Biocartis: Key Developments, 2020-2023

Table 92: Danaher Corp.: Key Developments, 2021-2022

Table 93: F. Hoffmann-La Roche Ltd.: Key Developments, 2021-2023

Table 94: Guardant Health Inc.: Key Developments, 2021-2022

Table 95: Hologic Inc.: Key Developments, 2021

Table 96: Illumina Inc.: Key Developments, 2021-2022

Table 97: Invivoscribe: Key Developments, 2020-2022

Table 98: Qiagen NV: Key Developments, 2021-2022

Table 99: Thermo Fisher Scientific Inc.: List of Pipeline Companion Diagnostics

Table 100: Thermo Fisher Scientific Inc.: Key Developments, 2021-2023

Table 101: Acronyms Used in This Report

List Of Figures

LIST OF FIGURES

Summary Figure A: Global Market for Companion Diagnostics, by Product and Service, 2019-2027

Summary Figure B: Global Market for Companion Diagnostics, by Region, 2019-2027

Figure 1: Companion Diagnostics Co-development Process from Biomarker Discovery to Regulatory Approval

Figure 2: Overview of the Key Priorities/Needs for CDx Tests Across Stakeholders

Figure 3: Global Market for Companion Diagnostics, by Product and Service, 2019-2027

Figure 4: Global Market Shares of Companion Diagnostics, by Product and Service, 2021

Figure 5: Global Market for Companion Diagnostics Instruments, by Region, 2019-2027

Figure 6: Global Market for Companion Diagnostics Consumables, by Region, 2019-2027

Figure 7: Global Market for Companion Diagnostics Services, by Region, 2019-2027

Figure 8: Global Market for Companion Diagnostics, by Type of Test, 2019-2027

Figure 9: Global Market Shares of Companion Diagnostics, by Type of Test, 2021

Figure 10: Global Market for Laboratory Developed Test (LDT)-CDx, by Region, 2019-2027

Figure 11: Global Market for Commercial-CDx, by Region, 2019-2027

Figure 12: Share of FDA-Approved CDx Tests, by Technology, 2000–June 2021

Figure 13: Global Market for Companion Diagnostics, by Technology, 2019-2027

Figure 14: Global Market Shares of Companion Diagnostics, by Technology, 2021

Figure 15: Global Market for Immunohistochemistry CDx, by Region, 2019-2027

Figure 16: Global Market for In Situ Hybridization CDx, by Region, 2019-2027

Figure 17: Global Market for Polymerase Chain Reaction CDx, by Region, 2019-2027

Figure 18: Global Market for Next-Generation Sequencing CDx, by Region, 2019-2027

Figure 19: Global Market for Genotyping CDx, by Region, 2019-2027

Figure 20: Global Market for Other CDx Technologies, by Region, 2019-2027

Figure 21: Global Market for CDx Services, by Region, 2019-2027

Figure 22: Global Market for Companion Diagnostics, by Application, 2019-2027

Figure 23: Global Market Shares of Companion Diagnostics, by Application, 2021

Figure 24: Global Market for Companion Diagnostics in Cancer Applications, by Region, 2019-2027

Figure 25: Global Market for Companion Diagnostics in Cancer Applications, by Cancer Type, 2019-2027

Figure 26: Global Market Shares of Companion Diagnostics in Cancer Applications, by

Cancer Type, 2021

Figure 27: Global Market for Companion Diagnostics in Neurologic Disorders Applications, by Region, 2019-2027

Figure 28: Global Market for Companion Diagnostics in Cardiovascular Disease Application, by Region, 2019-2027

Figure 29: Global Market for Companion Diagnostics in Infectious Disease Application, by Region, 2019-2027

Figure 30: Global Market for Companion Diagnostics in Other Disease Applications, by Region, 2019-2027

Figure 31: Global Market for Companion Diagnostics, by Region, 2019-2027

Figure 32: Global Market Shares of Companion Diagnostics, by Region, 2021

Figure 33: North American Market for Companion Diagnostics, by Country, 2019-2027

Figure 34: North American Market Shares of Companion Diagnostics, by Country, 2021

Figure 35: U.S. Market for Companion Diagnostics, 2019-2027

Figure 36: Canadian Market for Companion Diagnostics, 2019-2027

Figure 37: European Market for Companion Diagnostics, by Country, 2019-2027

Figure 38: European Market Shares of Companion Diagnostics, by Country, 2021

Figure 39: German Market for Companion Diagnostics, 2019-2027

Figure 40: U.K. Market for Companion Diagnostics, 2019-2027

Figure 41: French Market for Companion Diagnostics, 2019-2027

Figure 42: Cancer Incidence in Italy, by Cancer Type, 2020

Figure 43: Italian Market for Companion Diagnostics, 2019-2027

Figure 44: Rest of the European Market for Companion Diagnostics, 2019-2027

Figure 45: Asia-Pacific Market for Companion Diagnostics, by Country, 2019-2027

Figure 46: Asia-Pacific Market Shares of Companion Diagnostics, by Country, 2021

Figure 47: Cancer Incidence in China, by Cancer Type, 2020

Figure 48: Distribution Share of Cancer Incidence in China, by Cancer Type, 2020

Figure 49: Chinese Market for Companion Diagnostics, 2019-2027

Figure 50: Japanese Market for Companion Diagnostics, 2019-2027

Figure 51: Indian Market for Companion Diagnostics, 2019-2027

Figure 52: Rest of Asia-Pacific Market for Companion Diagnostics, 2019-2027

Figure 53: RoW Market for Companion Diagnostics, 2019-2027

Figure 54: Perspective of Different Stakeholders in CDx Market

Figure 55: Companion Diagnostics Business Models

Figure 56: Number of Patents Issued on Companion Diagnostics, by Year, 2018-2022

Figure 57: Number of Patents Issued on Companion Diagnostics, by Top Applicant, 2018-2022

Figure 58: Number of Patents Issued on Companion Diagnostics, by Top Owner, 2018-2022

- Figure 59: Clinical Trials on Companion Diagnostics, by Type of Study, March 2023
- Figure 60: Clinical Trials on Companion Diagnostics, by Status, March 2023
- Figure 61: Clinical Trials on Companion Diagnostics, by Phase, March 2023
- Figure 62: SWOT Analysis of the Global Companion Diagnostics Market
- Figure 63: Distribution Share of Global Cancer Incidence, by Region, 2020
- Figure 64: Estimated Global Cancer Incidence, by Region, 2020 vs. 2040
- Figure 65: Number of Personalized Medicines in the Global Drug Market, 2008-2020
- Figure 66: Abbott: Diagnostics Annual Revenue, 2019-2021
- Figure 67: Abbott: Diagnostics Market Share, by Business Segment, 2021
- Figure 68: Abbott: Diagnostics Market Share, by Region, 2021
- Figure 69: Adaptive Biotechnologies Corp.: Total Revenue, 2019-2021
- Figure 70: Adaptive Biotechnologies Corp.: Market Share, by Business Segment, 2021
- Figure 71: Agilent Technologies Inc.: Diagnostics and Genomics Revenue, 2019-2021
- Figure 72: Agilent Technologies Inc.: Market Share, by Business Segment, 2021
- Figure 73: Agilent Technologies Inc.: Market Share, by Region, 2021
- Figure 74: Biocartis: Total Revenue, 2019-2021
- Figure 75: Biocartis: Market Share, by Business Segment, 2021
- Figure 76: Biocartis: Market Share, by Geography, 2021
- Figure 77: Biodesix Inc.: Total Revenue, 2019-2021
- Figure 78: Biodesix Inc.: Market Share, by Business Segment, 2021
- Figure 79: Biodesix Inc.: Market Share, by Region, 2021
- Figure 80: bioMérieux SA: Total Revenue, 2019-2021
- Figure 81: bioMérieux SA: Market Share, by Business Segment, 2021
- Figure 82: bioMérieux SA: Market Share, by Region, 2021
- Figure 83: Bio-Techne Corp.: Total Revenue, 2019-2021
- Figure 84: Bio-Techne Corp.: Market Share, by Business Segment, 2021
- Figure 85: Bio-Techne Corp.: Market Share, Diagnostics, by Geography, 2021
- Figure 86: Danaher Corp.: Annual Revenue, 2019-2021
- Figure 87: Danaher Corp.: Market Share, by Business Segment, 2021
- Figure 88: Danaher: Market Share, by Geography, 2021
- Figure 89: F. Hoffmann-La Roche Ltd.: Total Revenue, 2019-2021
- Figure 90: F. Hoffmann-La Roche Ltd.: Market Share, by Business Segment, 2021
- Figure 91: F. Hoffmann-La Roche Ltd.: Market Share, by Region, 2021
- Figure 92: Hologic Inc.: Annual Revenue, 2019-2021
- Figure 93: Hologic Inc.: Market Share, by Business Segment, 2021
- Figure 94: Hologic Inc.: Market Share, by Region, 2021
- Figure 95: Illumina Inc.: Annual Revenue, 2019-2021
- Figure 96: Illumina Inc.: Market Share, by Business Segment, 2021
- Figure 97: Illumina Inc.: Market Share, by Region, 2021

Figure 98: Qiagen NV: Annual Revenue, 2019-2021

Figure 99: Qiagen NV: Market Share, by Business Segment, 2021

Figure 100: Qiagen NV: Market Share, by Region, 2021

Figure 101: Siemens Healthineers AG: Annual Revenue, 2019-2021

Figure 102: Siemens Healthineers AG: Market Share, by Business Segment, 2021

Figure 103: Siemens Healthineers AG: Market Share, by Region, 2021

Figure 104: Sysmex Corp.: Annual Revenue, 2019-2021

Figure 105: Sysmex Corp.: Market Share, by Business Segment, 2021

Figure 106: Sysmex Corp.: Market Share, by Region, 2021

Figure 107: Thermo Fisher Scientific Inc.: Annual Revenue, 2019-2021

Figure 108: Thermo Fisher Scientific Inc.: Market Share, by Region, 2021

Figure 109: Thermo Fisher Scientific Inc.: Market Share, by Business Segment, 2021

I would like to order

Product name: Companion Diagnostics: Technologies and Markets

Product link: <https://marketpublishers.com/r/C2893219268EN.html>

Price: US\$ 5,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C2893219268EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970